Tissue Diagnostics Market - Changing Supply and Demand Scenarios By 2030

Tissue Diagnostics Market Size, Share & Trends Analysis Report By Technology (ISH, Digital Pathology), By Application (Breast Cancer, Prostate Cancer), By End-use, By Region, And Segment Forecasts, 2023 - 2030

Tissue Diagnostics Market

The global tissue diagnostics market size was estimated at USD 5.19 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.15% from 2023 to 2030.

Tissue diagnostics remains a gold standard for cancer diagnosis as these technologies capture the anatomy of tumors. With rising incidences of cancer, the tissue diagnostics industry witnesses high demand with significant growth opportunities over the forecast period. The impact of COVID-19 on the tissue diagnostics industry has been significant. During the pandemic, there was a slowdown in routine medical procedures, including diagnostic testing, as healthcare resources were redirected toward managing the virus.

Gather more insights about the market drivers, restrains and growth of the Tissue Diagnostics Market

The pandemic led to a temporary decline in the demand for tissue diagnostics products and services. However, as the situation improved and healthcare systems adapted to the new normal, the market began to recover. The need for accurate diagnosis and monitoring of various diseases, including cancer, remained high, driving the demand for tissue diagnostics in the post-pandemic period.

Cancer incidences are increasing dramatically, which has caused a paradigm change in anatomic pathology. This, in turn, is contributing to the clinical pathology field's continued growth. Digitalization of diagnosis methods, increased use of liquid biopsy for cancer detection, and a continuous convergence of anatomical and molecular pathology. The importance of integrated bioinformatics and analyses increases as computational pathology gains momentum. Over the past two decades, the tissue diagnostics industry has changed as more advanced equipment has become available, making life easier for pathologists and physicians.

For instance, in May 2021, to increase the availability of precision medication for lung cancer, QIAGEN released its first FDA-approved tissue companion diagnostic to detect the KRAS G12C mutation in NSCLC tumors. The Rotor-Gene Q MDx instrument, a part of the modular QIAsymphony family of automation solutions, is used with the real-time qualitative PCR kit. This tool builds on QIAGEN's nine years of experience in researching and marketing KRAS CDx tests.

Globally, more than 14 million individuals are diagnosed with cancer each year, and by 2030, that figure is projected to increase to more than 21 million. Major market participants are introducing new cancer diagnosis products. For instance, Roche introduced its innovative BenchMark ULTRA PLUS system for cancer diagnostics in June 2022, enabling prompt, precise patient care. Pathologists can deliver high-quality, time-sensitive results to doctors and patients due to the BenchMark ULTRA PLUS tissue staining system's improved workflow, testing efficiency, and environmentally sustainable features.

Considering the rising worldwide cancer burden, various technologies, and improvements in tissue diagnostics (TDx) will increase pathology efficiency, which is essential for better cancer therapy and diagnosis. For example, Ibex Medical Analytics, the industry pioneer in AI-powered cancer diagnoses, and Alverno Laboratories announced a new deal in March 2023. It aims to expand the implementation of Ibex's Galen suite of Artificial Intelligence solutions to the entire Alverno network across Indiana and Illinois. The deployment comprises AI-powered solutions for cancer diagnosis across numerous tissue types and will help Alverno pathologists in providing the highest quality care for their patients.

A rise in the adoption rate of automated tissue-based diagnostic systems by research institutes enables them to diagnose tumors faster. In January 2023, MilliporeSigma announced its plans to expand its portfolio of antibodies for tissue diagnostics to help improve the classification of gliomas and other tumors in the nervous systems. Such RD investments will ensure the market continues to grow.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

The global hematologic malignancies market size was valued at USD 67.23 billion in 2023 and is projected to grow at a CAGR of 8.0% from 2024 to 2030.

The global precision diagnostics market size was estimated at USD 15.60 billion in 2023 and is projected to grow at a CAGR of 18.4% from 2024 to 2030.

Key Companies Market Share Insights

The tissue diagnostics market is fragmented due to the presence of several medium-to-small and large participants in the marketspace. The advent of novel diagnostic models by key players to enhance their technology portfolio has raised competitiveness in the market. For instance, in June 2022, Roche announced the launch of VENTANA DP 600 - the next-generation slide scanner. This high-capacity slide scanner provides the pathology lab with workflow flexibility and ease of use while producing stained histology slides with exceptional image quality from tissue samples. Some prominent players in the global tissue diagnostics market include:

  • Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • Siemens
  • Danaher
  • bioMérieux SA
  • QIAGEN
  • BD
  • Merck KGaA
  • GE Healthcare
  • BioGenex
  • Cell Signaling Technology, Inc.
  • Bio SB
  • DiaGenic ASA
  • Agilent Technologies

Order a free sample PDF of the Tissue Diagnostics Market Intelligence Study, published by Grand View Research.


Monica Nerkar

101 Blog posts

Comments